|Taxus Cardium Pharmaceuticals is an advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of Cardiac Microvascular Insufficiency due to advancing coronary artery disease, and Excellagen®, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics.|
|There are currently no news releases.|
Corporate Communications/Investor Relations
11750 Sorrento Valley Road
San Diego, CA 92121
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.